Structures, evolutionary relationships and expression profiles of the tumour necrosis factor superfamily and their receptors in black rockfish (Sebastes schlegelii).
Sign Up to like & getrecommendations! Published in 2022 at "Developmental and comparative immunology"
DOI: 10.1016/j.dci.2022.104405
Abstract: Members of tumour necrosis factor superfamily (TNFSF) and TNF receptor superfamily (TNFRSF) have crucial roles in many important biological processes such as cell proliferation, cell death, development, survival, immunity, and various diseases. The human TNFSF… read more here.
Keywords: tnfsf; tumour necrosis; factor superfamily; sebastes schlegelii ... See more keywords
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Sign Up to like & getrecommendations! Published in 2017 at "The Lancet"
DOI: 10.1016/s0140-6736(17)31429-0
Abstract: BACKGROUND Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy and… read more here.
Keywords: week; every weeks; tumour necrosis; inadequate response ... See more keywords
Evaluation of tumour necrosis factor alpha-stimulated gene-6 and fibroblast growth factor-2 levels in patients diagnosed with multi-system inflammatory syndrome in children.
Sign Up to like & getrecommendations! Published in 2023 at "Cardiology in the young"
DOI: 10.1017/s1047951123000355
Abstract: Investigations are still ongoing about the pathophysiology of multi-system inflammatory syndrome in children, which can progress with serious morbidity and mortality after COVID-19 infection. In this study, we aimed to investigate whether fibroblast growth factor-2… read more here.
Keywords: necrosis factor; factor; tumour necrosis; growth factor ... See more keywords
Tumour necrosis factor like cytokine 1A levels and lesion complexity in non-smoking patients with coronary artery disease
Sign Up to like & getrecommendations! Published in 2019 at "Biomarkers"
DOI: 10.1080/1354750x.2019.1685004
Abstract: Abstract Background: Tumour necrosis factor like cytokine 1A (TL1A), which is a member of tumour necrosis factor alpha superfamily (TNF-α), is a novel indicator of atherosclerosis. Objective: Smoking is an established stimulant of TNF-α. We… read more here.
Keywords: necrosis factor; syntax; complexity; tumour necrosis ... See more keywords
Tumour necrosis factor receptor-associated factors: interacting protein with forkhead-associated domain inhibition decreases inflammatory cell infiltration and cardiac remodelling after acute myocardial infarction.
Sign Up to like & getrecommendations! Published in 2020 at "Interactive cardiovascular and thoracic surgery"
DOI: 10.1093/icvts/ivaa060
Abstract: OBJECTIVES Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide. Post-AMI cardiac remodelling is closely related to the prognosis of AMI. The excess inflammatory responses could promote cardiac remodelling. Tumour necrosis… read more here.
Keywords: cardiac remodelling; tumour necrosis; factor; ami ... See more keywords
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.
Sign Up to like & getrecommendations! Published in 2023 at "Modern rheumatology"
DOI: 10.1093/mr/road038
Abstract: Tumour necrosis factor (TNF) inhibitors are currently the most widely used biological agents to treat rheumatoid arthritis. Ozoralizumab (OZR), a novel TNF inhibitor, is an antibody using variable heavy-chain domains of heavy-chain antibody (VHHs) and… read more here.
Keywords: necrosis factor; heavy chain; tumour necrosis; nonclinical clinical ... See more keywords
20 years of experience with tumour necrosis factor inhibitors: what have we learned?
Sign Up to like & getrecommendations! Published in 2018 at "Rheumatology"
DOI: 10.1093/rheumatology/key059
Abstract: TNF inhibitors are biologic DMARDs approved for the treatment of active RA in mid-1990s. They still represent a valuable therapeutic option to control the activity, disability and radiographic progression of the disease. In the context… read more here.
Keywords: years experience; factor inhibitors; experience tumour; tumour necrosis ... See more keywords
The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.
Sign Up to like & getrecommendations! Published in 2018 at "Rheumatology"
DOI: 10.1093/rheumatology/key209
Abstract: Objective To define the safety and efficacy of TNF inhibitors (TNFi) in RA patients with comorbidities. Methods A National Consensus Conference adopted a five-step process to better address the place of TNFi in the treatment… read more here.
Keywords: factor inhibitors; risk; necrosis factor; tumour necrosis ... See more keywords
Fig (Ficus exasperata and Ficus asperifolia)-Supplemented diet improves sexual function, endothelial nitric oxide synthase and suppresses tumour necrosis factor-alpha genes in hypertensive rats.
Sign Up to like & getrecommendations! Published in 2021 at "Andrologia"
DOI: 10.1111/and.14289
Abstract: We measured the effect of varieties of Fig leaves, Ficus exasperata Vahl. (FE) and Ficus asperifolia Miq (FA), commonly found in Sub-sahara Africa for managing hypertension on sexual performance in hypertensive rats, which is unknown.… read more here.
Keywords: ficus asperifolia; hypertensive rats; factor alpha; tumour necrosis ... See more keywords
Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15471
Abstract: To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non‐tumour necrosis factor inhibitor biologics (non‐TNFi biologics) compared to certolizumab pegol (CZP). read more here.
Keywords: necrosis factor; reported congenital; exposure non; congenital malformations ... See more keywords
Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.18623
Abstract: Efficacy data on therapies for patients with psoriasis who have failed tumour necrosis factor (TNF)‐α inhibitor therapy is limited. read more here.
Keywords: necrosis factor; inhibitor therapy; tumour necrosis;